Forte Biosciences, Inc. (FBRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the 2022 Annual Meeting of Stockholders held on June 1, 2022. The Company is incorporated in Delaware and its common stock trades on The NASDAQ Stock Market LLC under the symbol "FBRX". As of the record date of April 22, 2022, there were 14,761,261 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Of the outstanding shares, 8,322,250 shares were represented at the Annual Meeting. The following matters were voted upon:
- Election of Class II Directors: Steven Kornfeld and Patricia Walker, M.D., Ph.D. were elected to serve until the 2025 annual meeting.
- Steven Kornfeld: 3,366,874 votes for; 1,581,706 votes withheld.
- Patricia Walker: 3,335,739 votes for; 1,612,841 votes withheld.
- Ratification of Independent Auditor: The appointment of Mayer Hoffman McCann P.C. for the fiscal year ending December 31, 2022, was ratified.
- Votes For: 8,107,698
- Votes Against: 157,062
- Abstentions: 57,490
- Equity Incentive Plan Increase: Stockholders approved an increase to the shares reserved under the 2021 Equity Incentive Plan.
- Votes For: 2,826,803
- Votes Against: 2,106,190
- Abstentions: 15,587
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the amended 2021 Equity Incentive Plan following the stockholder approval.
- Confirm the tenure and specific responsibilities of the newly elected Class II directors.
- Note the significant number of broker non-votes (3,373,670) recorded for the director elections and the equity plan proposal.
- Review the Company's subsequent filings (e.g., 10-K or 10-Q) for financial metrics not included in this 8-K.